A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

December 18, 2022

Study Completion Date

January 5, 2023

Conditions

Hepatic Impairment

Interventions

DRUG

Molnupiravir

Four 200 mg capsules administered orally as a single dose

Trial Locations (3)

Thomas Jefferson University - Pharmacology and Experimental Therapeutics ( Site 0001), Philadelphia

Clinical Pharmacology of Miami ( Site 0003), Miami

Research Centers of America ( Hollywood ) ( Site 0002), Hollywood

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY